Check Capital Management Inc. CA Has $214,000 Holdings in Cardlytics, Inc. (NASDAQ:CDLX)

Check Capital Management Inc. CA lifted its stake in Cardlytics, Inc. (NASDAQ:CDLX) by 14.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 23,200 shares of the company’s stock after acquiring an additional 2,850 shares during the period. Check Capital Management Inc. CA owned 0.06% of Cardlytics worth $214,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Invesco Ltd. boosted its stake in Cardlytics by 538.1% during the 3rd quarter. Invesco Ltd. now owns 803,241 shares of the company’s stock valued at $13,253,000 after purchasing an additional 677,354 shares during the period. Norges Bank acquired a new position in shares of Cardlytics during the fourth quarter worth approximately $2,338,000. Two Sigma Advisers LP boosted its position in shares of Cardlytics by 664.7% in the third quarter. Two Sigma Advisers LP now owns 459,600 shares of the company’s stock valued at $4,320,000 after acquiring an additional 399,500 shares during the period. Baillie Gifford & Co. grew its stake in shares of Cardlytics by 30.7% in the fourth quarter. Baillie Gifford & Co. now owns 1,436,220 shares of the company’s stock worth $8,301,000 after acquiring an additional 337,252 shares during the last quarter. Finally, UBS Group AG grew its stake in shares of Cardlytics by 210.5% in the fourth quarter. UBS Group AG now owns 174,822 shares of the company’s stock worth $1,010,000 after acquiring an additional 332,961 shares during the last quarter. 68.10% of the stock is currently owned by institutional investors and hedge funds.

Cardlytics Stock Performance

Cardlytics stock traded up $0.28 on Friday, hitting $12.22. The company’s stock had a trading volume of 825,265 shares, compared to its average volume of 1,565,785. The company has a fifty day moving average price of $10.74 and a 200-day moving average price of $9.70. Cardlytics, Inc. has a one year low of $4.94 and a one year high of $20.52. The company has a current ratio of 1.31, a quick ratio of 1.31 and a debt-to-equity ratio of 1.91.

Cardlytics (NASDAQ:CDLX) last posted its earnings results on Thursday, March 14th. The company reported ($0.14) earnings per share for the quarter. The business had revenue of $89.17 million during the quarter. Cardlytics had a negative net margin of 43.56% and a negative return on equity of 25.38%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CDLX. Lake Street Capital increased their price target on shares of Cardlytics from $13.00 to $18.00 and gave the company a “buy” rating in a report on Friday, March 15th. Needham & Company LLC increased their target price on shares of Cardlytics from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, April 9th. Finally, Craig Hallum upgraded Cardlytics from a “hold” rating to a “buy” rating and boosted their price target for the company from $10.00 to $18.00 in a research note on Friday, March 15th.

Insider Activity at Cardlytics

In other Cardlytics news, COO Amit Gupta sold 72,658 shares of the stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $6.10, for a total transaction of $443,213.80. Following the completion of the transaction, the chief operating officer now directly owns 102,342 shares in the company, valued at $624,286.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Cardlytics news, COO Amit Gupta sold 72,658 shares of the company’s stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $6.10, for a total transaction of $443,213.80. Following the sale, the chief operating officer now directly owns 102,342 shares of the company’s stock, valued at $624,286.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Clifford Sosin acquired 350,000 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were purchased at an average cost of $13.40 per share, with a total value of $4,690,000.00. Following the acquisition, the insider now owns 6,023,676 shares of the company’s stock, valued at approximately $80,717,258.40. The disclosure for this purchase can be found here. Insiders have sold a total of 85,272 shares of company stock valued at $616,010 in the last 90 days. 0.78% of the stock is owned by corporate insiders.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.